#United States #New York #Class Action #Cytokinetics #CYTK

Class Action Lawsuit Against Cytokinetics, Inc. (CYTK)

In the latest development regarding investor protection, The Gross Law Firm has initiated a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK). This action prompts shareholders who bought shares within a specific period to engage proactively in pursuit of recovery for their incurred losses. Investors are encouraged to reach out and secure their position in this ongoing legal battle.

What Happened?

The class action revolves around a series of allegations against Cytokinetics concerning misleading communications about their New Drug Application (NDA) for aficamten. During the class period of December 27, 2023, to May 6, 2025, the defendants purportedly issued materially false information regarding the timeline and approval processes linked to their NDA submission to the U.S. Food and Drug Administration (FDA).

In particular, Cytokinetics allegedly suggested that the FDA's approval for aficamten was expected to occur in the latter half of 2025, aligning with a PDUFA date of September 26, 2025. However, they reportedly failed to disclose critical risks involved in submitting their NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could potentially delay regulatory approval.

This omission was notably highlighted during a May 6, 2025, earnings call, where it was disclosed that Cytokinetics had multiple pre-NDA meetings with the FDA regarding safety and risk concerns yet chose not to include a REMS with their submission. This decision reflected a conscious awareness of the potential need for such measures, leading to claims that Cytokinetics intentionally misled investors about the regulatory timeline. As a result, shareholders acquired CYTK shares at artificially inflated prices, ultimately suffering significant financial losses when these truths emerged.

Important Dates for Investors

Shareholders are reminded of the crucial deadline of November 17, 2025, to register their claims within this class action. Potential lead plaintiffs must also express their interest before this date to ensure they are represented adequately. Investors who believe they qualify should register as soon as possible to protect their interests.

What Steps Should Shareholders Take?

Once registered, shareholders will be automatically enrolled in a portfolio monitoring tool, providing crucial updates throughout the lifecycle of the case. Participating in this class action carries no cost or obligation, allowing shareholders to take crucial steps towards recovering their losses without financial risk.

Why Choose The Gross Law Firm?

The Gross Law Firm stands as a nationally recognized firm advocating for investor rights against fraudulent business practices. Their commitment lies in holding companies accountable to adhere to ethical standards and ensure transparency with shareholders. The firm extends its services to those affected by misleading statements or omissions that led to significant stock price inflation, thereby enabling investors to reclaim their investments.

For more information or to join the class action, shareholders are encouraged to reach out directly to The Gross Law Firm. With skilled attorneys ready to assist, this initiative serves as a reminder of the importance of shareholder rights in the face of corporate wrongdoing.

Contact Information

For queries, investors can contact The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: 646-453-8903

In this climate of corporate accountability, it's vital for shareholders to remain vigilant and proactive about their investments. Engaging in class action lawsuits like the one against Cytokinetics is a crucial step in seeking justice and financial recovery.